Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

RPTX Repare Therapeutics Inc

3,07

0,10 (3,37%)

23 Nov 2024 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more Repare Therapeutics Charts.

Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Click Here for more Repare Therapeutics Charts.

News Repare Therapeutics Inc

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Dienstag 12 November 2024 (2 Wochen vor) • Business Wire

Form 424B5 - Prospectus [Rule 424(b)(5)]
Donnerstag 7 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 7 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 7 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Donnerstag 7 November 2024 (2 Wochen vor) • Business Wire

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Mittwoch 23 Oktober 2024 (1 Monat vor) • Business Wire

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Montag 14 Oktober 2024 (1 Monat vor) • Business Wire

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Montag 30 September 2024 (2 Monate vor) • Business Wire

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Montag 23 September 2024 (2 Monate vor) • Business Wire

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
Freitag 13 September 2024 (2 Monate vor) • Business Wire

Weitere Repare Therapeutics Inc News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen